tbuckley/cabot-search huggingface dataset:
SAT0168 Long Term Efficacy and Safety of Infliximab in the Treatment of BehÇEt’S Disease
Authors: P. Leccese, L. Latanza, A. Padula, A. Nigro, S. D’Angelo, M. Gilio, C. Palazzi, I. Olivieri
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To evaluate the efficacy and safety of long-term administration of Infliximab in BD patients refractory to conventional therapy. <h3>Methods</h3> In this ongoing, prospective, longitudinal and observational study BD patients unresponsive to conventional therapy with corticosteroids plus at least two different immunosuppressive drugs were treated with Infliximab therapy (5 mg/kg intravenously at weeks 0, 2, 6, and every 6-8 weeks subsequently). Response to anti-TNF therapy was based on the expert opinion and was graded as follows: remission, response, no response and worsening. Remission was defined as the complete disappearance of symptoms and signs of inflammation and response as at least 50% of improvement. <h3>Results</h3> Since 2003, 68 BD patients (45 M/23 F; mean age 33.9±11.2 yrs; mean disease duration 12.4±9.5 yrs; 67% HLA-B51 positive) were enrolled. Indication for Infliximab treatment were uveitis in 35 patients, severe mucocutaneous manifestations in 14, CNS vasculitis in 11, optic neuritis in 1, intestinal involvement in 2, arthritis in 2, seizure in 2, vascular involvement in the remaining 1. The median duration of infliximab treatment was 25.5 months (range 1-106 months). Infliximab therapy resulted in a remission in 20 patients with uveitis, in 6 with CNS involvement, in 3 with severe mucocutaneous manifestations, in 1 with optic neuritis, in 1 with arthritis and in 1 with vascular involvement. A response was observed in 4 patients with mucocutaneous manifestations. The drug was stopped for lack of efficacy in 4 patients with severe mucocutaneous manifestations, 2 with uveitis, 2 with CNS vasculitis, 1 with seizure. Seventeen BD patients stopped infliximab therapy for loss of efficacy. Six BD patients discontinuated infliximab treatment for serious adverse events (5 for infusion reactions, 1 for bacterial pneumonia). Adverse events not requiring drug discontinuation were observed in 7 patients (mild infusion reactions in 2, upper respiratory tract infection in 6, urinary tract infection in 1). <h3>Conclusions</h3> In our experience infliximab has been showed effective and safe in a long-term follow-up in patients with refractory BD. <h3>Disclosure of Interest</h3> None Declared
Abstract 1675: Effects of calcium and vitamin D on TGFβ and TGFβ1 expression in rectal mucosa of sporadic colorectal adenoma patients: A randomized controlled trial
Authors: Huakang Tu, Carrie Daniel, Thomas Ahearn, Roberd Bostick, Amparo Gonzalez-Feliciano
Journal: Cancer Research (2012)

Abstract Aim: To estimate the effects of supplemental calcium and vitamin D3 on the expression of TGFβ and TGFβ1 (growth-promoting and -inhibiting autocrine/paracrine growth factors, respectively) in the normal-appearing colorectal mucosa in sporadic colorectal adenoma patients. Methods: We conducted a pilot, randomized, double-blind, placebo-controlled, 2 x 2 factorial clinical trial (n = 92) of calcium 2 g and/or vitamin D3 800 IU/day versus placebo over 6 months. TGFβ and TGFβ1 expression was measured in biopsies of normal-appearing rectal mucosa using automated immunohistochemistry and quantitative image analysis at baseline and 6-months follow-up. Results: The mean overall expression of TGFβ1 in the whole crypts increased by 14% (P = 0.25), 19% (P = 0.17), and 22% (P = 0.09) in the calcium, vitamin D, and calcium plus vitamin D groups, respectively, relative to the placebo group. The increases in TGFβ1 appeared to be uniform along the full length of the crypts. While there were no substantial changes in the overall expression of TGFβ in the whole crypts, in the calcium, vitamin D, and calcium plus vitamin D groups, TGFβ decreased by 14% (P = 0.35), 2% (P = 0.86), and 1% (P = 0.93), respectively, in the upper 40% (differentiation zone) of the crypts, but increased by 29% (P = 0.30), 38% (P = 0.17), and 25% (P = 0.32) in the bottom 60% of the crypts (proliferative zone). Also, a TGFβ/TGFβ1 ratio was created as an indicator of the balance between the growth-promoting and -inhibiting factors; in the upper 40% of the crypts it was found to have decreased by 35% (P = 0.24), 25% (P = 0.42), and 51% (P = 0.09) in the calcium, vitamin D, and calcium plus vitamin D groups, respectively, relative to the placebo group, but not to have changed substantially in the whole or bottom 60% of the crypts. Conclusions: These preliminary results suggest that supplemental calcium and vitamin D3 may increase the expression of TGFβ1, shift the expression of TGFβ downward in the colorectal crypts, and decrease the ratio of TGFβ to TGFβ1 in the upper 40% (differentiation zone) of the crypts in the normal-appearing colorectal mucosa of sporadic colorectal adenoma patients, and support further investigation of calcium and vitamin D3 as chemopreventive agents against colorectal neoplasms. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1675. doi:1538-7445.AM2012-1675
Vulnerabilities to misinformation in online pharmaceutical marketing
Authors: Julian De Freitas, Brian A Falls, Omar S Haque, Harold J Bursztajn
Journal: Journal of the Royal Society of Medicine (2013)

Given the large percentage of Internet users who search for health information online, pharmaceutical companies have invested significantly in online marketing of their products. Although online pharmaceutical marketing can potentially benefit both physicians and patients, it can also harm these groups by misleading them. Indeed, some pharmaceutical companies have been guilty of undue influence, which has threatened public health and trust. We conducted a review of the available literature on online pharmaceutical marketing, undue influence and the psychology of decision-making, in order to identify factors that contribute to Internet users’ vulnerability to online pharmaceutical misinformation. We find five converging factors: Internet dependence, excessive trust in the veracity of online information, unawareness of pharmaceutical company influence, social isolation and detail fixation. As the Internet continues to change, it is important that regulators keep in mind not only misinformation that surrounds new web technologies and their contents, but also the factors that make Internet users vulnerable to misinformation in the first place. Psychological components are a critical, although often neglected, risk factor for Internet users becoming misinformed upon exposure to online pharmaceutical marketing. Awareness of these psychological factors may help Internet users attentively and safely navigate an evolving web terrain.
Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma
Authors: Atsushi Ichikawa, Tomohiro Kinoshita, Takashi Watanabe, Hirokazu Kato, Hirokazu Nagai, Keitaro Tsushita, Hidehiko Saito, Tomomitsu Hotta
Journal: New England Journal of Medicine (1997)

Mutations of the p53gene are associated with a poor prognosis in several types of cancer. We investigated the prognostic importance of p53 mutations in patients with aggressive B-cell lymphoma.
THU0089 Hepatocyte Growth Factor Receptor (C-MET) Signaling Pathway Regulates Synovial Cell Production of Inflammatory Mediators and Osteoblast Differentiation
Authors: M. Sekiguchi, S. Tsunemi, S. Kitano, H. Sano, T. Iwasaki
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rheumatoid arthritis (RA) is characterized by the aggressive synovial expansion due to angiogenesis and subsequent destruction of the underlying cartilage and bone. New blood vessel formation is critically important for synovial expansion in RA. Hepatocyte growth factor (HGF) enhances angiogenesis and impairs bone formations. Therefore, the abrogation of HGF receptor (c-Met)-mediated signaling events appears to be a promising strategy for the prevention of synovial cell proliferations and bone destructions. <h3>Objectives</h3> In the present study we examined the role of HGF receptor (c-Met) signaling pathway for synovial cell function and osteoblast differentiation using human synovial cell line and mouse myoblastic cell line which differentiate into osteoblast in vitro. <h3>Methods</h3> HGF or c-Met expressions in synovial tissues were examined by immunohistochemistry using either anti-HGF Ab or anti-c-Met Ab. Human MH7A synovial cell line was established by transfection with SV40 T antigen to synovial cells which were isolated from knee joint intraarticular soft tissue of RA patients. IL-6, prostaglandin (PG) E2, and matrix metalloproteinase (MMP)-3 production from MH7A cells was determined by ELISA. C2C12 mouse myoblast cell line was cultured with bone morphogenic protein (BMP)-2 and alkaline phosphatase (ALP) activity in the cells was determined using an ALP staining kit. Osteocalcin production by C2C12 cells was determined by ELISA. Extracellular signal-regulated kinase (ERK) 1/2 phosphorylation was determined by Western blot analysis. The effect of MEK1/2 inhibitor or c-Met kinase inhibitor was examined by the treatment of the cells with either U0126 or SU11274, respectively. <h3>Results</h3> HGF and c-Met expressions in RA synovium were increased comparing to those in osteoarthritis synovium, suggesting the increased HGF receptor signaling in RA synovial cells. We also detected HGF and c-Met expressions in MH7A and C2C12 cells. TNF-alpha significantly enhanced the production of IL-6, PGE2, and MMP-3 by MH7A cells. The blocking of c-Met signaling pathway by c-Met kinase inhibitor slightly enhanced TNF-alpha-induced IL-6 and PGE2 production but significantly inhibited MMP-3 production by MH7A cells. In addition, c-Met kinase inhibitor significantly enhanced ALP and osteocalcin production by BMP-2 stimulated C2C12 cells. These c-Met kinase inhibitor effects were resucued by MEK1/2 inhibitor, indicating that c-Met signaling pathway activates ERK1/2. <h3>Conclusions</h3> These results indicate that c-Met signaling pathway activates ERK1/2 and enhances MMP-3 production by synovial cells and inhibits osteoblast differentiation. Blocking the c-Met signaling pathway may inhibits synovial expansion and enhances osteoblast differentiation and become a new therapeutic approach for the treatment of RA. <h3>Disclosure of Interest</h3> None Declared
FRI0067 The relationship between fructose intake, alcohol consumption and serum URIC acid levels and the risk of inflammatory polyarthritis. Results from the european prospective investigation of cancer and the norfolk arthritis register: The EPIC-2-noar study:
Authors: M. Lahiri, C. Morgan, R.N. Luben, M. Lentjes, D.K. Bunn, M. Lunt, S.M. Verstappen, D.P. Symmons, K.-T. Khaw, N.J. Wareham, I.N. Bruce
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Increased alcohol intake and fructose consumption may be associated with a lower risk of inflammatory arthritis. The mechanism of action may be related to a rise in serum uric acid (SUA), a circulating anti-oxidant. <h3>Objectives</h3> To examine the association between intake of alcohol, red wine, beer and fructose, and SUA with risk of inflammatory polyarthritis (IP). <h3>Methods</h3> Lifestyle data were obtained from 25,455 adults without IP and aged 40-79 using a health and lifestyle questionnaire (HLQ) in the population-based European Prospective Investigation of Cancer (EPIC-Norfolk) study from 1994-97. Over 342,916 person-years of follow-up, 184 individuals who subsequently developed IP were identified by linkage with the Norfolk Arthritis Register (NOAR), a primary-care based disease register. Controls were taken from a random sample of 4000 EPIC participants (case-cohort design), which due to overlap between cases and availability of 7-day diet diaries (7DD) resulted in a dataset of 4098 participants, of which 171 had IP. <h3>Results</h3> Correlation between the HLQ and 7DD for alcohol intake was good (ρ =0.8). The median (IQR) SUA for cases and unaffected cohort was 280.6 (237.7, 356.4) and 287.7 (235.7, 345.6) μmol/L respectively. In linear regression SUA showed a weak but significant association with alcohol intake in men (β coeff 4.17 (2.61,5.73), p&lt;0.001, adj r<sup>2</sup>=0.02) and a weak negative association with fructose intake (mainly from fruits) in women (β coeff -0.37 (-0.75,0.00), p=0.05, adj r<sup>2</sup>&lt;0.01). In a Cox proportional hazards model stratified for gender and adjusted for age and smoking, there was no association between SUA and risk of IP (Table). Alcohol intake (HLQ) was associated with a lower risk of IP in women, while fructose intake was associated with a lower risk of IP in men and a similar trend in women. We found no specific effect for red wine or beer consumption. <h3>Conclusions</h3> Fructose and alcohol intake may have gender specific influences on the development of future IP. Such effects are, however, unlikely to be mediated by the uric acid-allantoin anti-oxidant pathway. <h3>Disclosure of Interest</h3> None Declared
Cerebral Infarction on 99mTc-MDP SPECT/CT Imaging
Authors: Jia Guo, Shuang Hu, Haitao Wang, Anren Kuang
Journal: Clinical Nuclear Medicine (2013)

A 70-year-old man with lung cancer underwent whole-body MDP bone scintigraphy to evaluate bone metastases that showed marked tracer uptake in the right side of the head, suggestive of skull metastasis. SPECT/CT imaging was performed for further evaluation. The SPECT images demonstrated increased MDP activity in the region of the brain perfused by the right middle cerebral artery. On CT images, there was a large hypoattenuation area corresponding to elevated MDP accumulation. At the same day, magnetic resonance angiography of the brain revealed occlusion of the right middle cerebral artery.
A6.44 Only BAFF mRNA, not BAFF protein level in blood, is associated with SLE activity over one year
Authors: E Zollars, H Fang, J Bienkowska, J Czerkowicz, A Ranger, N Allaire, A Thai, J Browning, L Magder, M Petri
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> B-cell–activating factor (BAFF; also known as B lymphocyte stimulator or BLyS) is a prominent factor in the selection and survival of B cells. BAFF has been demonstrated to be elevated in the blood of systemic lupus erythematosus (SLE) patients and is implicated in the pathogenesis of the disease. We have shown that BAFF gene expression level (mRNA) in whole blood associates with same day disease activity and predicts future activity in SLE patients. The concentration of the BAFF protein in serum has also been used as a marker of disease activity. In this study, we investigated the utility of BAFF mRNA versus protein level as a predictor of future global disease activity in SLE patients. <h3>Methods</h3> 292 patients (59% Caucasian, 34% African-American, 92% female, mean age 46 ± 12 years) were enrolled in a prospective observational study. At baseline, BAFF gene expression level was measured in peripheral blood RNA (PAXgene) using quantitative PCR. Serum BAFF (protein) levels were measured using the Rules Based Medicine platform. The number of visits per patient over the following year ranged from 1–9. Six patients had 1 visit, 46 patients had 2–3 visits, 159 patients had 4 visits, and 81 patients had more than 4 visits. P-values were calculated using generalised estimating equations as implemented in SAS 9.2. P-values were then adjusted for ethnicity. <h3>Results</h3> By two separate measures, PGA (physician global assessment) and SLEDAI, higher levels of measured BAFF mRNA were associated with higher levels of disease activity. The association with SLEDAI was stronger. Multiple measures of disease activity including proteinuria, anti-dsDNA antibodies and hypocomplementemia were also associated with higher levels of BAFF mRNA. This same association was NOT seen with the serum BAFF protein. Higher levels of BAFF protein were only associated with elevated anti-dsDNA antibodies, not global measures of disease activity. <h3>Conclusion</h3> BAFF mRNA at the baseline visit was strongly associated with global disease activity, urine protein/creatinine ≥0.5, serologies, and ESR over the next year. In contrast, BAFF protein level in the blood at baseline only correlated with anti-dsDNA over the next year. This study supports the use of BAFF mRNA level in peripheral blood rather than protein as a predictive biomarker of disease activity in SLE patients.
Transhepatic endoscopic gastrostomy
Authors: Pascale Mercky, Aude Goffic, Philippe Ah-Soune
Journal: Endoscopy (2014)

A 55-year-old woman was referred for insertion of a percutaneous endoscopic gastrostomy (PEG) feeding tube prior to surgical treatment of a squamous cell carcinoma of the tongue. Clinical signs and biological data did not indicate liver disease, except for chronic alcohol consumption. A 20-Fr gastrostomy tube (MIC PEG tube; Kimberly-Clark Health Care) was placed endoscopically using the pull technique [1] after transillumination and finger pressure, without any immediate complications.
Abstract 5363: HER-2 over-expression in a subset of soley estrogen-induced breast tumors in intact female ACI rat
Authors: Sara Antonia Li, Yan Hong, Jonathan J. Li
Journal: Cancer Research (2010)

Abstract Breast cancer comprises about 30% of all cancers occurring in USA women. Gene profiling expression data of human breast cancer have characterized luminal A and B subtypes, comprising 73% of all breast cancers in women, as exhibiting both estrogen receptor alpha (ERα) and progesterone receptor (PR) positivity, as well as over-expression of FOX-A1 and GATA-3 transcription factors, and primarily p53wt. It is well established that 25-30% of these human breast cancers exhibit amplification of the gene or over-expression of the protein product of human epidermal growth factor receptor-2 [HER-2/neu, also known as epidermal growth factor receptor 2 (ErbB-2)], a tyrosine kinase transmembrane receptor involved in signal transduction pathways leading to cell growth and differentiation, and playing a crucial role in the acceleration and evolution of cancer. In breast cancer, its over-expression is associated with poor prognosis and increased metastatic potential. We have shown that the intact female ACI rat breast tumor model induced by estrogen remarkably recapitulates the aforementioned luminal A/B subtypes of human breast cancer, both in its histopathological progression and molecular alterations. In addition, this estrogen-induced mammary tumor is characterized by c-myc amplification, cyclin E1, MDM2, and Aurora A/B mitotic kinase over-expression, centrosome over-duplication, chromosomal instability, and aneuploidy; the defining feature of human breast cancer. Employing western blot analyses, we now report that 29% of 17β-estradiol-induced primary ACI rat breast tumors exhibited pronounced levels of HER-2/neu expression. Immunohistochemical analyses revealed that the HER-2/neu over-expression was confined to pre-invasive lesions, cribiform and comedo ductal carcinomas in-situ (DCIS), and primary invasive tumors, suggesting that estrogen is in some manner involved in initiating its over-expression in a subset of these breast tumors. However, the large majority of estrogen-elicited mammary tumors in ACI rats were essentially devoid of HER-2/neu expression. [Supported by the Susan G. Komen for the Cure Grants BCTR42906 and BCTR0600996]. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5363.
AB0534 Efficacy and safety to use halfdose abatacept therapy between 24weeks in patients with rheumatoid arthritis in japanese
Authors: H. Ishikawa, A. Kaneko, D. Kida, T. Sato, T. Kojima, N. Ishiguro
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In recent years, biological agents are widely used for the treatment of rheumatoid arthritis (RA) and there are several registries for the treatment of RA in other countries. However, in Japan, these studies are limited. Now, we set up the registry of RA patients treated using biological agents named Tsurumai Biologics Communication (TBC) and collected 2072 cases until now [1]. Abatacept is recognized as one of the treatment for RA patients with no effect of anti-TNF agents by EULAR recommendation [2] and it is used in more than 50 countries. It came to be used newly in Japan since September, 2010. <h3>Objectives</h3> Clinical Phase II trials in Japan, ACR improvement <sup>rates</sup>, compared with placebo showed significantly improvement in the group of ABT (abatacept) 2 mg/kg and 10 mg/kg. The purpose of this research was to evaluate the patient who reduced the dose of ABT by 250mg (5 mg/kg). <h3>Methods</h3> The efficacy, safety, continuity were evaluated of 15 cases in TBC registry which treat half amount (250 mg) dose of ABT.Background Patients - average age 60.1 and average disease duration 12.4 years, 12 females, 3 males, 53.7kg average body weight, the dosage is 5.3mg/kg body weight in terms of average, 13 cases combined with MTX, 13 cases of Bio naive. <h3>Results</h3> Disease activities before the start of treatment, 6 patients were high disease activity, 3 patients were moderate disease activity, 1 patients were low disease activity,and 5 patient was remission. At 24 weeks after treatment, 5 patients because of inadequate response, which was continued back to the normal dose, 10 cases were continued at half dose, all patients confirmed the improvement in disease activity. Serious adverse events in all 15 cases have not been observed. <h3>Conclusions</h3> In our reports, half dose of ABT treatment is potentially as an alternative treatment to the patients such as elderly patients or in response to economic reasons. <h3>References</h3> Kojima T, et al. Mod Rheumatol. 2011 [Epub ahead of print]. Osef S et al. Ann Rheum Dis 2010 69:964-975. <h3>Disclosure of Interest</h3> None Declared
Normal Thymic Uptake of 2-Deoxy-2[F-18]fluoro-D-Glucose
Authors: HALUK ALIBAZOGLU, BUKET ALIBAZOGLU, EDWARD F. HOLLINGER, SHARYN A. INGRAM, WILLIAM A. WILLOUGHBY, GREGORY LaMONICA, AMJAD ALI
Journal: Clinical Nuclear Medicine (1999)

Whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) positron emission tomography (PET) of a 54-year-old woman with a history of recurrent thyroid follicular cancer and an elevated thyroglobulin level showed significant FDG uptake in the thyroid bed and anterior mediastinum. A previous scan after high-dose I-131 therapy also showed iodine uptake in these regions. Because of a lack of response to iodine therapy, the patient had surgery. Recurrent thyroid cancer was found in the neck, but the mediastinal lesion was shown to consist of normal thymus tissue. In repeated examinations performed after surgery, there was no uptake of FDG or I-131 in the anterior mediastinum. Previous treatment with a high dose of radioiodine may have contributed to visualization of a normal adult thymus with FDG PET.
739 PSYCOLOGICAL PROFILE AND HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)
Authors: V.O. Palmieri, M. Lozupone, P. de Bonfils, M. Barberio, F. Minerva, O. Todarello, G. Palasciano
Journal: Journal of Hepatology (2012)
FDG Positron Emission Tomographic Scintigraphy Can Reveal Castleman’s Disease as a Cause of Inflammation
Authors: DANIEL BLOCKMANS, ALEX MAES, SIGRID STROOBANTS, HERMAN BOBBAERS, LUC MORTELMANS
Journal: Clinical Nuclear Medicine (2001)

BLOCKMANS, DANIEL M.D., Ph.D.*; MAES, ALEX M.D., Ph.D.†; STROOBANTS, SIGRID M.D.†; BOBBAERS, HERMAN M.D., Ph.D.*; MORTELMANS, LUC M.D., Ph.D.† Author Information